Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEARCA:AORNASDAQ:FABNASDAQ:OKYO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAORiShares Core 60/40 Balanced Allocation ETF$58.86-0.3%$57.25$52.97▼$59.77$2.37B0.64232,676 shs132,563 shsFABFirst Trust Multi Cap Value AlphaDEX Fund$77.80-0.4%$76.57$67.96▼$90.30$112.81M1.223,689 shs1,646 shsOKYOOKYO Pharma$1.85+0.5%$1.36$0.81▼$1.98$62.60M-0.38131,758 shs2.46 million shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAORiShares Core 60/40 Balanced Allocation ETF0.00%-1.06%+3.17%-0.12%+5.50%FABFirst Trust Multi Cap Value AlphaDEX Fund0.00%-3.81%+2.87%-5.62%-3.83%OKYOOKYO Pharma0.00%+25.00%+22.38%+65.92%+23.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAORiShares Core 60/40 Balanced Allocation ETFN/AN/AN/AN/AN/AN/AN/AN/AFABFirst Trust Multi Cap Value AlphaDEX FundN/AN/AN/AN/AN/AN/AN/AN/AOKYOOKYO Pharma1.6859 of 5 stars3.53.00.00.00.91.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAORiShares Core 60/40 Balanced Allocation ETF 0.00N/AN/AN/AFABFirst Trust Multi Cap Value AlphaDEX Fund 2.51Moderate Buy$77.80N/AOKYOOKYO Pharma 3.00Buy$7.00278.38% UpsideCurrent Analyst Ratings BreakdownLatest FAB, FUM, OKYO, and AOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2025OKYOOKYO PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAORiShares Core 60/40 Balanced Allocation ETFN/AN/AN/AN/AN/AN/AFABFirst Trust Multi Cap Value AlphaDEX FundN/AN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/A($0.20) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAORiShares Core 60/40 Balanced Allocation ETFN/AN/A19.83∞N/AN/AN/AN/AN/AFABFirst Trust Multi Cap Value AlphaDEX FundN/AN/A12.75∞N/AN/AN/AN/AN/AOKYOOKYO Pharma-$16.83MN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAORiShares Core 60/40 Balanced Allocation ETF$1.552.63%N/AN/AN/AFABFirst Trust Multi Cap Value AlphaDEX Fund$1.602.06%N/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/ALatest FAB, FUM, OKYO, and AOR DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/26/2025FABFirst Trust Multi Cap Value AlphaDEX FundQuarterly$0.19500.97%3/27/20253/27/20253/31/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAORiShares Core 60/40 Balanced Allocation ETFN/AN/AN/AFABFirst Trust Multi Cap Value AlphaDEX FundN/AN/AN/AOKYOOKYO PharmaN/A0.28N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAORiShares Core 60/40 Balanced Allocation ETFN/AFABFirst Trust Multi Cap Value AlphaDEX FundN/AOKYOOKYO Pharma2.97%Insider OwnershipCompanyInsider OwnershipAORiShares Core 60/40 Balanced Allocation ETFN/AFABFirst Trust Multi Cap Value AlphaDEX FundN/AOKYOOKYO Pharma40.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAORiShares Core 60/40 Balanced Allocation ETFN/A40.20 millionN/ANot OptionableFABFirst Trust Multi Cap Value AlphaDEX Fund147,0001.45 millionN/ANot OptionableOKYOOKYO Pharma733.84 million20.15 millionNot OptionableFAB, FUM, OKYO, and AOR HeadlinesRecent News About These CompaniesOKYO Pharma CEO to present drug research for debilitating eye pain at Boston summitMay 19, 2025 | proactiveinvestors.comOKYO Pharma CEO to Present at Boston Drug Discovery SummitMay 19, 2025 | tipranks.comOKYO Pharma Limited CEO to Present on Urcosimod Development for Neuropathic Corneal Pain at GPCRs-Targeted Drug Discovery SummitMay 19, 2025 | quiverquant.comOKYO Pharma to Present at the GPCRs-Targeted Drug Discovery SummitMay 19, 2025 | globenewswire.comUS FDA grants fast track designation to OKYO Pharma’s urcosimod to treat neuropathic corneal painMay 3, 2025 | pharmabiz.comOKYO moves toward FDA talks after eye drug trial – ICYMIMay 2, 2025 | proactiveinvestors.comOKYO moves toward FDA talks after eye drug trial – ICYMIMay 2, 2025 | proactiveinvestors.comFDA grants fast track designation to OKYO Pharma’s urcosimod for treatment of neuropathic corneal painMay 1, 2025 | ophthalmologytimes.comOKYO Pharma secures FDA fast-track designation for urcosimod for neuropathic corneal painMay 1, 2025 | proactiveinvestors.comFDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal PainMay 1, 2025 | manilatimes.netOKYO Pharma accelerates clinical development of urcosimod for neuropathic corneal painApril 30, 2025 | proactiveinvestors.comOKYO Pharma Accelerates Urcosimod Development for Neuropathic Corneal PainApril 30, 2025 | tipranks.comOKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal PainApril 30, 2025 | globenewswire.comOKYO Pharma CEO discusses FDA Fast Track filing for urcosimod - ICYMIApril 5, 2025 | proactiveinvestors.comOKYO Pharma confirms stability of drug candidateApril 2, 2025 | uk.investing.comOKYO Pharma releases positive long-term stability data for urcosimod in neuropathic corneal painMarch 31, 2025 | ophthalmologytimes.comOKYO Pharma reports long-term shelf stability of corneal pain treatmentMarch 31, 2025 | proactiveinvestors.comOKYO Pharma Announces Positive Data in Long-Term Stability of UrcosimodMarch 31, 2025 | globenewswire.comOKYO Pharma Files Application for Fast Track Designation for Urcosimod in Treatment of Neuropathic Corneal PainMarch 12, 2025 | nasdaq.comOKYO Pharma seeks FDA Fast Track for eye pain drugMarch 12, 2025 | uk.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumNVIDIA Stock Surges on Bullish News: How High Could It Climb?By Thomas Hughes | May 13, 2025View NVIDIA Stock Surges on Bullish News: How High Could It Climb?5 Reasons the Rebound in Microchip Technology Stock Is RealBy Thomas Hughes | May 12, 2025View 5 Reasons the Rebound in Microchip Technology Stock Is RealFAB, FUM, OKYO, and AOR Company DescriptionsiShares Core 60/40 Balanced Allocation ETF NYSEARCA:AOR$58.86 -0.18 (-0.30%) Closing price 05/23/2025 04:10 PM EasternExtended Trading$58.90 +0.04 (+0.07%) As of 05/23/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iShares Growth Allocation ETF, formerly iShares S&P Growth Allocation Fund (the Fund), is an open-end management investment company. The Fund seeks investment results that correspond generally to the price and yield performance of the S&P Target Risk Growth Index (the Growth Allocation Index). The Growth Allocation Index seeks to measure the performance of an asset allocation strategy targeted to a growth-focused risk profile. The Fund is designed for investors seeking moderate capital appreciation and opportunity for current income and capital preservation. The Fund's investment advisor is BlackRock Fund Advisors.First Trust Multi Cap Value AlphaDEX Fund NASDAQ:FAB$77.80 -0.33 (-0.42%) As of 05/23/2025 03:57 PM EasternThe First Trust Multi Cap Value AlphaDEX Fund (FAB) is an exchange-traded fund that is based on the NASDAQ AlphaDEX Multi Cap Value index. The fund tracks an index that uses fundamental factors to select and weight value stocks from the Nasdaq US Select Indices. FAB was launched on May 8, 2007 and is managed by First Trust.OKYO Pharma NASDAQ:OKYO$1.85 +0.01 (+0.54%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$1.80 -0.06 (-2.97%) As of 05/23/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
